Zacks Research Has Positive Outlook of Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for Surmodics in a report issued on Monday, November 25th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of ($0.08) per share for the quarter, up from their previous forecast of ($0.12). The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q1 2026 earnings at $0.22 EPS.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. The business had revenue of $33.23 million during the quarter, compared to analyst estimates of $30.69 million. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%.

A number of other research firms also recently weighed in on SRDX. StockNews.com initiated coverage on shares of Surmodics in a report on Saturday, November 23rd. They set a “hold” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research report on Thursday, November 7th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $50.00.

Surmodics Trading Down 0.1 %

Shares of SRDX stock opened at $39.54 on Thursday. Surmodics has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The company has a quick ratio of 3.22, a current ratio of 3.96 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $566.45 million, a P/E ratio of -48.81 and a beta of 1.20. The stock has a 50-day simple moving average of $38.51 and a 200 day simple moving average of $39.58.

Insider Activity

In related news, CFO Timothy J. Arens sold 7,009 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now directly owns 70,350 shares of the company’s stock, valued at approximately $2,774,604. The trade was a 9.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.90% of the stock is owned by corporate insiders.

Institutional Trading of Surmodics

Several institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. bought a new position in Surmodics during the 3rd quarter worth $1,190,000. Renaissance Technologies LLC increased its position in shares of Surmodics by 5.0% in the second quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock worth $25,499,000 after purchasing an additional 28,990 shares during the period. Gardner Lewis Asset Management L P bought a new position in shares of Surmodics in the second quarter worth $8,531,000. Sagefield Capital LP acquired a new position in Surmodics in the second quarter valued at about $2,350,000. Finally, Trium Capital LLP bought a new stake in Surmodics during the second quarter worth about $1,406,000. 96.63% of the stock is currently owned by institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).